Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
105
Frequently Asked Questions
What is market cap of Progenics Pharmaceuticals, Inc.?
The market cap of Progenics Pharmaceuticals, Inc. is $355.05M
What is the 52 week high for Progenics Pharmaceuticals, Inc.?
The 52 week high for Progenics Pharmaceuticals, Inc. is $6.37.
What is the 52 week low for Progenics Pharmaceuticals, Inc.?
The 52 week low for Progenics Pharmaceuticals, Inc. is $1.89.
What is Progenics Pharmaceuticals, Inc. stock price today?
Progenics Pharmaceuticals, Inc.' stock price today is $4.10.
What is the pe ratio of Progenics Pharmaceuticals, Inc.?
The PE ratio of Progenics Pharmaceuticals, Inc. is None.
What is the price to book ratio of Progenics Pharmaceuticals, Inc.?
The price to book ratio of Progenics Pharmaceuticals, Inc. is 11.5976.
What is Progenics Pharmaceuticals, Inc.'s EBITDA?
Progenics Pharmaceuticals, Inc.'s EBITDA is -61.343.
What is the 50-day moving average of Progenics Pharmaceuticals, Inc.?
The 50-day moving average of Progenics Pharmaceuticals, Inc. is 4.0627.
How many employess does Progenics Pharmaceuticals, Inc. has?
Progenics Pharmaceuticals, Inc. has 105 employees.